Clinical Trials on Primary Mediastinal Lymphoma

Total 68134 results

M.D. Anderson Cancer Center

Recruiting

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy (PACIFIC)

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma

United States
Jennifer Crombie, MD
Merck Sharp & Dohme LLC

Recruiting

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Primary Mediastinal Large B Cell Lymphoma | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma Refractory | Primary Mediastinal Large B-Cell Lymphoma Recurrent | Epstein-Barr Virus Positive Diffuse Large...

United States
David Bond, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | Transformed Non-Hodgkin Lymphoma | Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage... and other conditions

United States
The Third Xiangya Hospital of Central South University

Recruiting

Clinical Research on a Novel Deep-learning Based System in Mediastinal Endoscopic Ultrasound Scanning

Mediastinum Disease

China
National Cancer Institute (NCI)

Active, not recruiting

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal Large B-Cell Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

United States
National Research Center for Hematology, Russia

Recruiting

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Primary Mediastinal Lymphoma

Russian Federation
Bambino Gesù Hospital and Research Institute

Recruiting

CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML

Acute Lymphoblastic Leukemia | Diffuse Large B Cell Lymphoma | Primary Mediastinal Lymphoma

Italy
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

Primary Mediastinal B-cell Lymphoma

Norway, United Kingdom, Italy, Switzerland, Czechia, United States, China, Argentina, Canada, Germany, Poland, Portugal, Sweden, Ukraine
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Primary Mediastinal Large B-Cell Lymphoma

United States, Canada, Australia, Puerto Rico
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Active, not recruiting

Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

Primary Mediastinal Large B Cell Lymphoma

France, Belgium, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain
Chinese PLA General Hospital

Unknown

Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

Primary Mediastinal Large B-cell Lymphoma

China
Fondazione Italiana Linfomi ONLUS

Completed

A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL (FIL_SGN01)

Primary Mediastinal Large B Cell Lymphoma

Italy
International Extranodal Lymphoma Study Group (IELSG)

Completed

A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma

Primary Mediastinal B-Cell Lymphoma

Italy, United Kingdom, Switzerland, Spain
IRCCS San Raffaele

Active, not recruiting

CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)

Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Taizhou HoudeAoke Biomedical Co., Ltd.

Not yet recruiting

Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

China
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study

Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Italy
Centre Henri Becquerel

Recruiting

Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL) (CAMIL)

Primary Mediastinal Large B-cell Lymphoma

France
IRCCS San Raffaele

Recruiting

Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); AstraZeneca; Juno Therapeutics, Inc.; MedImmune...

Terminated

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Terminated

Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)

China
Epizyme, Inc.

Completed

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

B-cell Lymphomas (Phase 1) | Advanced Solid Tumors (Phase 1) | Diffuse Large B-cell Lymphoma (Phase 2) | Follicular Lymphoma (Phase 2) | Transformed Follicular Lymphoma | Primary Mediastinal Large B-Cell Lymphoma

Australia, Canada, France, Germany, Italy, Poland, Taiwan, Ukraine, United Kingdom, United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Hodgkin's Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Canada, United States, Brazil, Czechia, France, Italy, Poland, Russian Federation, South Africa, Turkey, Ukraine
Malaghan Institute of Medical Research
Wellington Zhaotai Therapies Limited (WZTL)

Recruiting

ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) (ENABLE)

Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Lymphomas Non-Hodgkin's B-Cell | Transformed Follicular Lymphoma (TFL) | Primary Mediastinal B-cell Lymphoma (PMBCL)

New Zealand
Ruijin Hospital

Recruiting

Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL

Primary Mediastinal Large B Cell Lymphoma | EBV-Positive DLBCL, Nos

China
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent... and other conditions

United States
Samsung Medical Center

Completed

Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma (JAK2)

Primary Mediastinal Large B-cell Lymphoma | Relapsed or Refractory Hodgkin Lymphoma

Korea, Republic of
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma | Refractory Primary Mediastinal (Thymic)... and other conditions

United States
Medical University of Warsaw
Warsaw University of Technology

Unknown

Virtual Bronchoscopy (VB) vs. Endobronchial Ultrasound (EBUS) Guided Mediastinal Sampling (VB/EBUS-TBNA)

Lung Cancer, | Mediastinal Tumors, | Lymphomas, | Sarcoidosis,

Poland
Nicola Goekbuget

Completed

Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults

Lymphoblastic Lymphoma | Burkitt's Lymphoma | Mediastinal Neoplasms | Burkitt's Leukemia | Large Cell Anaplastic Lymphoma

Germany
TCR2 Therapeutics

Completed

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Follicular Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma

United States
Azienda Socio Sanitaria Territoriale degli Spedali...

Recruiting

Bio-CAR-T BS Study

Acute Lymphoblastic Leukemia (ALL) | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Diffuse Large B Cell Lymphoma (DLBCL)

Italy
Paolo Corradini
Annalisa Chiappella; Cristiana Carniti; Anna Dodero

Recruiting

Italian Observational Study on CAR-T Therapy for Lymphoma (CART-SIE)

Follicular Lymphoma | Mantle Cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Diffuse Low Grade B-Cell Lymphoma

Italy
Medivation, Inc.

Withdrawn

Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Lymphoma, Large B-Cell, Diffuse | Primary Mediastinal Large B-cell Lymphoma | Transformed Indolent Lymphoma

United States
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy

Recruiting

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | CD20 Positive | Refractory Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Refractory... and other conditions

United States
CureTech Ltd

Completed

CT-011 MAb in DLBCL Patients Following ASCT

Primary Mediastinal Large B-Cell Lymphoma | Lymphoma, Large Cell, Diffuse | Lymphoma, Mixed Cell, Diffuse

United States, Israel, India
Acepodia Biotech, Inc.

Recruiting

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Marginal Zone Lymphoma | Non Hodgkin Lymphoma | DLBCL | Primary Mediastinal Large B Cell Lymphoma

United States, Taiwan
Eden BioCell Ltd.
National Taiwan University Hospital

Terminated

RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

Taiwan
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
Adicet Bio, Inc

Recruiting

A Phase 1 Study of ADI-001 in B Cell Malignancies (GLEAN-1)

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma

United States
Adicet Bio, Inc

Enrolling by invitation

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma

United States
Fred Hutchinson Cancer Center
Nektar Therapeutics

Recruiting

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent Grade 3b Follicular Lymphoma | Refractory Grade 3b Follicular... and other conditions

United States
New York Medical College
Roswell Park Cancer Institute

Recruiting

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE)

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Non-Hodgkin Lymphoma | Primary Mediastinal B-cell Lymphoma | CD20+ Lymphoblastic Lymphoma | Follicular Lymphoma, Grade III

United States
Institute of Hematology & Blood Diseases Hospital
Shanghai Cell Therapy Engineering Technology Research Center Group Co., Ltd.

Unknown

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Transformed Lymphoma

China
Czech Lymphoma Study Group
Hoffmann-La Roche; Ministry of Health, Czech Republic

Completed

R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas (R-MCEB)

Diffuse Large B-Cell Lymphoma. | Primary Mediastinal B-Cell Lymphoma | Follicular Lymphoma Grade III

Czech Republic
AIDS Malignancy Consortium
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center

Not yet recruiting

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

HIV Infection | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent... and other conditions
Epizyme, Inc.

Completed

Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumor | Diffuse Large B Cell Lymphoma | Primary Mediastinal Lymphoma

United States
Second Affiliated Hospital, School of Medicine,...

Completed

Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma

Transformed Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma

China
M.D. Anderson Cancer Center

Recruiting

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Recurrent High Grade B-Cell... and other conditions

United States
National Cancer Institute (NCI)

Completed

CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma

Primary Mediastinal B-cell Lymphoma | Diffuse, Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma | Mantle Cell

United States

Clinical Trials on Primary Mediastinal Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations